Navigation Links
Lilly Commences Cash Tender Offer for ImClone Systems at $70 Per Share
Date:10/14/2008

INDIANAPOLIS, Oct. 14 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) announced today that its wholly-owned subsidiary, Alaska Acquisition Corporation, has commenced its tender offer for all outstanding shares of ImClone Systems Incorporated (Nasdaq: IMCL) at a price of $70.00 net per share in cash. Lilly and ImClone previously announced that they had reached a definitive merger agreement for Lilly to acquire ImClone.

The Board of Directors of ImClone has unanimously determined that the offer and the merger are fair to, and in the best interests of, ImClone and its shareholders; approved and declared advisable the merger agreement and the transactions contemplated thereby, including the offer; and recommended that holders of shares of ImClone common stock accept the offer and tender their shares in the offer.

There is no financing condition to the tender offer. The tender offer is subject to certain conditions set forth in the Offer to Purchase referenced below, including a minimum share tender condition, the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and other governmental approvals.

Unless the tender offer is extended, the tender offer and any withdrawal rights to which ImClone's shareholders may be entitled will expire at 12:00 midnight, EST, on Thursday, November 20, 2008. Following the acceptance for payment of shares in the tender offer and completion of the transactions contemplated in the merger agr
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
2. Lilly Declares Fourth-Quarter Dividend
3. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
4. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
5. Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
6. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
7. Lilly Announces Termination of AIR Insulin Program
8. HistoRx and Lilly Extend, Expand AQUA(R) Analysis Partnership
9. Pelikan Technologies and Lilly Form Alliance to Promote Diabetes Education
10. Lilly Reports Solid First-Quarter Results
11. Lilly CEO Praises Massachusetts Leadership in Biotech, Urges Policy Prescriptions to Help Ensure States Investment Generates Dividends and Jobs

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009).... 9 NexBio, Inc. announced the pre...College of Allergy, Asthma, and Immunology in Miam... (Fludase®), a Sialidase, Decreases Airway Re...in Animal Models of Asthma". ,, DAS181 (Fludase...t-targeting drug candidate being studied in human ...
(Date:11/9/2009)...vember 9 Following the provision o...Drug Administration (FDA), privately,owned UK comp...international.com ) has been informed that its inn...n awarded an Orphan-Drug,designation for the treat..., ALS, also known as Lou Gehrig,s disease, is ...
(Date:11/6/2009)...6 /PRNewswire-FirstCall/ - Microbix Biosystems Inc...iled the Form 52-109F1 Certification of Annual Fil...r and James Long, the Chief Financial Officer (the...in connection with the annual audited financial st..., The Company initially filed the annual financi...
(Date:11/6/2009)...stria, November 6 EUCODIS Bioscien...ng, and marketing enzymes for the,chemical industr...rch,agreement with Bio Sidus, the leading biopharm... agreement gives EUCODIS Bioscience exclusive acce...o Sidus, proprietary collection of,psychrophilic b...
Breaking Biology Technology:NexBio(R) Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009 2NexBio(R) Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009 3EUCODIS Bioscience to Explore Novel Enzymatic Activities in Antarctic Bacteria Library From Bio Sidus 2
...ed for the First Time on 50 mg/Day Dose for PRISTI...ssive Disorder, COLLEGEVILLE, Pa., Dec. 12 Wyeth...), announces that data from,two Phase 3 clinical s...gational serotonin-norepinephrine reuptake inhibit... a 50 mg/day dose of PRISTIQ for the,treatment of ...
...he Netherlands, December 12 , - Forty-five Presti...Response to Customer Demand, Elsevier, a leading ...M) information, today announced that 45 French-lan...e available on ScienceDirect beginning January,3, ...gie, Journal de Chirurgie and,La Press Medicale, r...
...IND has Been Filed With the FDA for the Fourth Gen...Collaboration with Roche., COPENHAGEN, December 1...nvestigational New Drug application (IND) for a,Ge...oration with Roche has,been filed with the FDA by ...velopment of the antibody which selectively blocks...
Other Biology Technology:New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 2New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 3New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 4New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 5New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 6ScienceDirect to Host French-Language Journals from Elsevier Masson 2ScienceDirect to Host French-Language Journals from Elsevier Masson 3Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic 2Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic 3
(Date:11/4/2009)...t Norman has received more than $10 million in res... the federal stimulus program, bringing thetotal a...rs to $23 million. Thirty-three projects achieved...logy to weather. , "The university has thoughtfu...reasof scholarly excellence to federal agency prio...
(Date:11/4/2009)...PRNewswire-FirstCall/ -- Quest Diagnostics Incorpo...of diagnostic testing, information and services, a...r 30, 2009, income from continuing operations rose... $160 million, or $0.81 per diluted share, for the...ults were reduced by a $0.03 per share charge asso...
(Date:11/4/2009)... Aware, Inc. (Nasdaq: AW...nd biometrics software, today reported financial r...2009. ,, Michael Tzannes, Aware,s Chairman an...e announced an agreement to sell our DSL and home ...semiconductor company being spun out of Infineon. ...
Breaking Biology News(10 mins):OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 2OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 3Quest Diagnostics Reports Strong Performance in Third Quarter 2009 2Quest Diagnostics Reports Strong Performance in Third Quarter 2009 3Quest Diagnostics Reports Strong Performance in Third Quarter 2009 4Quest Diagnostics Reports Strong Performance in Third Quarter 2009 5Quest Diagnostics Reports Strong Performance in Third Quarter 2009 6Quest Diagnostics Reports Strong Performance in Third Quarter 2009 7Quest Diagnostics Reports Strong Performance in Third Quarter 2009 8Quest Diagnostics Reports Strong Performance in Third Quarter 2009 9Quest Diagnostics Reports Strong Performance in Third Quarter 2009 10Quest Diagnostics Reports Strong Performance in Third Quarter 2009 11Quest Diagnostics Reports Strong Performance in Third Quarter 2009 12Quest Diagnostics Reports Strong Performance in Third Quarter 2009 13Quest Diagnostics Reports Strong Performance in Third Quarter 2009 14Quest Diagnostics Reports Strong Performance in Third Quarter 2009 15Quest Diagnostics Reports Strong Performance in Third Quarter 2009 16Quest Diagnostics Reports Strong Performance in Third Quarter 2009 17Aware, Inc. Reports Third Quarter 2009 Financial Results 2Aware, Inc. Reports Third Quarter 2009 Financial Results 3Aware, Inc. Reports Third Quarter 2009 Financial Results 4Aware, Inc. Reports Third Quarter 2009 Financial Results 5Aware, Inc. Reports Third Quarter 2009 Financial Results 6Aware, Inc. Reports Third Quarter 2009 Financial Results 7Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product 13449 1Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product 13449 2Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product 13449 3EGEN Inc Announces the Promotion of Jason Fewell Ph D to Vice President of Preclinical Research and Development 13448 1EGEN Inc Announces the Promotion of Jason Fewell Ph D to Vice President of Preclinical Research and Development 13448 2NeurogesX Reports Second Quarter 2009 Results 13446 1NeurogesX Reports Second Quarter 2009 Results 13446 2NeurogesX Reports Second Quarter 2009 Results 13446 3NeurogesX Reports Second Quarter 2009 Results 13446 4NeurogesX Reports Second Quarter 2009 Results 13446 5NeurogesX Reports Second Quarter 2009 Results 13446 6NeurogesX Reports Second Quarter 2009 Results 13446 7NeurogesX Reports Second Quarter 2009 Results 13446 8NeurogesX Reports Second Quarter 2009 Results 13446 9NeurogesX Reports Second Quarter 2009 Results 13446 10NeurogesX Reports Second Quarter 2009 Results 13446 11NeurogesX Reports Second Quarter 2009 Results 13446 12
...rrow Neurological Institute at St. Joseph,s Hospit...k between eye motions and the perception of illuso...Stephen Macknik, PhD, director of the Laboratory o...e, PhD, director of the Laboratory of Visual Neuro...illan; conducted a study based on the Enigma paint...
... have grown soybeans and turned them into many use...hy a soybean grows, blooms or produces like it doe... , University of Georgia professor Wayne Parrott...million grant from the National Science Foundation...ue. , "I,m convinced that soybeans would be so mu...
... city dwellers posed by Southern California wildfi...restimated by officials. , Detailed particulate a...ia wild fires indicates that the composition posed...generally realized, according to a new paper analy...thern California. , The paper, entitled "Physico...
Other Biology News:Soybean grant gives researchers tools to unravel better bean 2Where there's wildfire smoke, there's toxicity 2
...ade; is a recombinant preparation of the catalytic...Enterokinase is expressed and isolated from the ye...yme preparation (2). It recognizes the sequence As...er the lysine residue. The enzyme can be used to c...
...in U-23 (rat) - Diluted Antiserum for RIA, Host: R... Products, Host: Rabbit Antigen sequence: H-Tyr-...y-Gly-Phe-Phe-Leu-Phe-Arg-Pro-Arg-Asn-NH 2 For ou...ptide, please see Neuromedin U-23 (rat) (H-9295) a...
Mae II from Roche Applied Science
Xho I from Roche Applied Science
Biology Products: